China SPE: Memory/ advanced logic capacity expansion drives growth ahead; Valuation framework reset on better long-term visibility

Allen Chang
+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Verena Jeng
+852-2978-1681 | verena.jeng@gs.com
Goldman Sachs (Asia) L.L.C.

Ting Song
+852-2978-6466 | ting.song@gs.com
Goldman Sachs (Asia) L.L.C.

We are constructive on China SPE and semi material names, riding on rising advanced node capacity expansion and the generative AI trend to support China semis ecosystem development. Media reported (Link) the long-term supply agreement between CXMT and Tencent on the DRAM chips for servers, suggesting strong demand from local clients and mix upgrade towards high-end applications. We review the valuation framework of China SPE and semi material names (NAURA/ AMEC/ ACMR/ Anji Micro) and change the valuation methodology to 2030E discounted P/E on better long-term visibility given customers' rising capex and rising localization. Maintain Buy on NAURA, AMEC, ACMR and Anji Micro. Read more: Global Chips Act 3.

New memory agreement with CSP clients: Media reported that (Link) the memory supplier CXMT has signed a multi-year supply agreement with Tencent on the server DRAM chips, and the value worth more than Rmb20bn. We are positive on the progress of local memory and advanced logic suppliers to fulfill rising demand from local CSP clients in China on generative AI demand, which is positive to the China semis supply chain across foundry, SPE, semi material, components, IP and design.

NAURA (002371.SZ, Buy)

Earnings revision: We raise earnings by 0.3%/ 1%/ 5% in 2026-28E mainly on higher earnings and improving Opex ratio. Revenues are revised up on higher revenues of deposition and etching tools, reflecting higher capex spending from memory clients' capacity expansion. We revise down Opex ratio in 2028E on improving operational efficiency and larger scale.

Exhibit 1: Earnings revision

	2026E			2027E			2028E		
Rmb mn	New	Old	Diff(%)	New	Old	Diff(%)	New	Old	Diff(%)
Revenue	51,517	51,454	0.1%	66,438	66,035	1%	81,803	79,552	3%
Gross profit	20,449	20,422	0.1%	26,877	26,700	1%	33,499	32,503	3%
Op. income	8,055	8,028	0.3%	14,974	14,869	1%	19,252	18,330	5%
Net income	7,777	7,754	0.3%	13,410	13,322	1%	17,127	16,355	5%
Margins									
GM	39.7%	39.7%		40.5%	40.4%		41.0%	40.9%	
OPM	15.6%	15.6%		22.5%	22.5%		23.5%	23.0%	
NM	15.1%	15.1%		20.2%	20.2%		20.9%	20.6%	

Source: Company data, Goldman Sachs Global Investment Research

Valuation: We change the valuation methodology from near-term P/E to 2030E discounted P/E to capture the long-term growth opportunities. **Our 12-month**

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

target price is Rmb1,200 (vs. previously at Rmb818). Our target multiple is based the correlation between peers' P/E vs. the sum of forward year NI growth and OPM, which is 56x 2030E discounted P/E target multiple, based on company's NI YoY at 25% and OPM at 25% in 2031E. We apply the 56x target P/E and discount it back to 2027E with a COE of 11%. Maintain Buy.

Exhibit 2: NAURA discounted P/E

Rmb mn	2023	2024	2025	2026E	2027E	2028E	2029E	2030E	2031E
Revenue	**22,079**	**29,838**	**39,353**	**51,517**	**66,438**	**81,803**	**101,120**	**125,543**	**153,869**
Rev YoY %		*35%*	*32%*	*31%*	*29%*	*23%*	*24%*	*24%*	*23%*
Gross margin	41.1%	42.9%	40.1%	39.7%	40.5%	41.0%	41.3%	41.6%	41.8%
Gross profit	9,075	12,787	15,782	20,449	26,877	33,499	41,777	52,246	64,358
Opex	**5,479**	**7,043**	**10,742**	**12,394**	**11,903**	**14,247**	**17,439**	**21,313**	**26,044**
Opex ratio	25%	24%	27%	24%	18%	17%	17%	17%	17%
OP income	**3,596**	**5,743**	**5,040**	**8,055**	**14,974**	**19,252**	**24,337**	**30,933**	**38,313**
OPM	*16%*	*19%*	*13%*	*16%*	*23%*	*24%*	*24%*	*25%*	*25%*
Pre-tax profit	**4,466**	**6,511**	**5,845**	**9,102**	**15,792**	**20,207**	**25,614**	**32,647**	**40,689**
Net profit	**3,899**	**5,621**	**5,522**	**7,777**	**13,410**	**17,127**	**21,680**	**27,601**	**34,374**
YoY	233%	44%	-2%	41%	72%	28%	27%	27%	25%
EPS	5.45	7.83	7.64	10.74	18.51	23.64	29.93	38.10	47.45
2030 Target P/E								56.0x	
12M target price (Rmb)					**1,200**				
TP implied P/E					**65**	**51**	**40**		

COE assumption	
Beta	1.20
Risk free	3.5%
Market risk premium	6.5%
COE	**11%**


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 3: NAURA P&L Summary

(Rmb m)	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26E	3Q26E	4Q26E	2024	2025	2026E	2027E	2028E
Revenue	8,206	7,936	11,160	12,052	10,323	10,495	14,759	15,940	29,838	39,353	51,517	66,438	81,803
Gross profit	3,530	3,277	4,498	4,477	4,209	4,091	5,826	6,323	12,787	15,782	20,449	26,877	33,499
Operating expense	1,843	1,849	2,483	4,567	2,656	2,054	2,740	4,944	7,043	10,742	12,394	11,903	14,247
Operating income	1,687	1,428	2,015	(90)	1,553	2,037	3,086	1,380	5,743	5,040	8,055	14,974	19,252
Pre tax profit	1,813	1,527	1,963	542	1,815	2,298	3,348	1,641	6,511	5,845	9,102	15,792	20,207
Net income	1,581	1,627	1,922	392	1,635	1,929	2,962	1,345	5,621	5,522	7,777	13,410	17,127
Margins / ratio													
Gross margin	43.0%	41.3%	40.3%	37.2%	40.8%	39.0%	39.5%	39.7%	42.9%	40.1%	39.7%	40.5%	41.0%
Opex ratio	22.5%	23.3%	22.2%	37.9%	25.7%	19.6%	18.6%	31.0%	23.6%	27.3%	24.1%	17.9%	17.4%
Operating margin	20.6%	18.0%	18.1%	-0.7%	15.0%	19.4%	20.9%	8.7%	19.2%	12.8%	15.6%	22.5%	23.5%
Net margin	19.3%	20.5%	17.2%	3.2%	15.8%	18.4%	20.1%	8.4%	18.8%	14.0%	15.1%	20.2%	20.9%
QoQ													
Revenue	-13%	-3%	41%	8%	-14%	2%	41%	8%					
Gross profit	-7%	-7%	37%	0%	-6%	-3%	42%	9%					
Pre tax profit	23%	-16%	29%	-72%	235%	27%	46%	-51%					
Net income	36%	3%	18%	-80%	317%	18%	54%	-55%					
YoY													
Gross profit	39%	7%	33%	18%	19%	25%	30%	41%	41%	23%	30%	31%	25%
Operating income	55%	-17%	16%	nm	-8%	43%	53%	nm	60%	-12%	60%	86%	29%
Pre tax profit	36%	-19%	8%	-63%	0%	50%	71%	203%	46%	-10%	56%	74%	28%
Net income	40%	-2%	14%	-66%	3%	19%	54%	243%	44%	-2%	41%	72%	28%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 4: NAURA 12M forward P/E



Source: Eikon Datastream

Exhibit 5: NAURA Balance sheet and Cash flow statement

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Balance sheet						
Cash & equivalent	12,451	12,347	17,337	19,215	22,622	31,058
Net receivables	4,712	6,864	9,290	9,058	14,605	14,531
Inventory	16,992	23,479	28,627	39,200	46,084	56,725
Other current asset	4,070	3,521	4,066	4,066	4,066	4,066
Total current assets	38,226	46,211	59,321	71,540	87,377	106,380
Net PP&E	3,352	6,205	7,568	8,885	10,183	11,466
Net intangibles	2,547	4,703	10,520	8,821	7,476	6,411
Total investments	3	66	300	300	300	300
Other long-term assets	9,496	8,524	12,091	12,091	12,091	12,091
Total assets	**53,625**	**65,709**	**89,801**	**101,637**	**117,427**	**136,648**
Account payables	7,858	12,190	15,544	20,500	24,746	29,706
Short-term debt	62	2,127	1,871	1,871	1,871	1,871
Total current liabilities	19,083	23,482	26,180	31,137	35,383	40,342
Long-term debt	5,835	3,946	12,973	12,973	12,973	12,973
Total long-term liabilities	9,717	10,002	19,693	19,693	19,693	19,693
Total liabilities	**28,800**	**33,484**	**45,873**	**50,829**	**55,076**	**60,035**
Total common equity	**24,367**	**31,082**	**37,726**	**44,719**	**56,376**	**70,751**
Minority interest	458	1,144	6,202	6,089	5,975	5,862
Total Equity	**24,825**	**32,225**	**43,928**	**50,808**	**62,352**	**76,613**
Cash conversion cycle						
Account receivable days	75	71	75	65	65	65
Inventory days	421	433	403	398	393	388
Account payable days	193	215	215	212	209	206
Cash conversion cycle	303	289	264	252	250	248
Ratios						
ROE (common)	17.7%	20.3%	16.1%	18.9%	26.5%	26.9%
ROA	8.1%	9.4%	7.1%	8.1%	12.2%	13.5%

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Cash flow statement						
Net income	3,899	5,621	5,522	7,777	13,410	17,127
D&A add-back	633	1,006	1,503	2,732	2,471	2,283
Minorities add-back	134	72	(113)	(113)	(113)	(113)
Net(inc)/dec working capital	(2,354)	(4,306)	(4,221)	(5,384)	(8,184)	(5,607)
Other operating cash flow	51	(816)	(557)	-	-	-
Cash flow from operations	2,365	1,573	2,133	5,012	7,584	13,690
Capital expenditures	(1,980)	(2,046)	(2,262)	(2,350)	(2,424)	(2,501)
Investments	(70)	(166)	(495)	-	-	-
Others	(8)	0	(1,173)	-	-	-
Cash flow from investments	**(2,058)**	**(2,212)**	**(3,929)**	**(2,350)**	**(2,424)**	**(2,501)**
Dividend paid (common & pref)	(388)	(615)	(908)	(783)	(1,753)	(2,753)
Inc/(dec) in debt	1,889	175	8,771	-	-	-
Change in common stock	2	3	191	-	-	-
Other financing cash flows	142	1,174	(1,450)	-	-	-
Cash flow from financing	**1,647**	**740**	**6,607**	**(783)**	**(1,753)**	**(2,753)**
Total cash flow	**2,017**	**(104)**	**4,990**	**1,878**	**3,407**	**8,436**
Ratio						
Capex to revenue	9.0%	6.9%	5.7%	4.6%	3.6%	3.1%

Source: Company data, Goldman Sachs Global Investment Research

AMEC (688012.SS, Buy)

Earnings revision: We cut 2026 earnings by 1%, and raise earnings by 1%/ 7% in 2027-28E mainly on higher earnings and improving Opex ratio. Revenues are revised up on higher revenues of etching tools for advanced node clients, supporting company's product mix upgrade. We revise down Opex ratio in 2027E to reflect better operational efficiency and production site management.

Exhibit 6: Earnings revision

	2026E			2027E			2028E		
Rmb m	Old	New	Diff (%)	Old	New	Diff (%)	Old	New	Diff (%)
Revenue	17,004	17,004	0%	22,679	22,899	1%	28,078	29,518	5%
Gross profit	7,194	7,194	0%	9,938	10,039	1%	12,575	13,231	5%
Op. income	3,536	3,492	-1%	6,178	6,233	1%	8,361	8,965	7%
Net income	4,088	4,049	-1%	5,954	6,002	1%	7,701	8,214	7%
Margins									
GM	42.3%	42.3%	0ppts	43.8%	43.8%	0ppts	44.8%	44.8%	0ppts
OPM	20.8%	20.5%	-0.3ppts	27.2%	27.2%	0ppts	29.8%	30.4%	0.6ppts
NM	24.0%	23.8%	-0.2ppts	26.3%	26.2%	0ppts	27.4%	27.8%	0.4ppts

Source: Company data, Goldman Sachs Global Investment Research

Valuation: Our 12-month target price is Rmb573 (vs. previously at Rmb412.08), still based on a discounted P/E methodology. Our target multiple is based the correlation between peers' P/E vs. the sum of forward year NI growth and OPM, which is 56x 2030E discounted P/E (vs. previously at 44.2x 2030E P/E). The 56x target 2030E P/E is supported by higher earnings growth and sector re-rate on positive outlook of semis capacity expansion and advanced nodes upgrade. We apply the 56x target P/E and discount it back to 2027E with a COE of 11% (unchanged). Maintain Buy.

Exhibit 7: AMEC discounted P/E

Rmb mn	2022	2023	2024	2025	2026E	2027E	2028E	2029E	2030E	2031E
Revenue	**4,740**	**6,264**	**9,065**	**12,385**	**17,004**	**22,899**	**29,518**	**37,783**	**47,607**	**58,080**
Etcher	3,147	4,703	7,276	9,832	12,759	17,259	22,045	28,217	35,553	43,375
MOCVD	700	462	379	717	928	1,073	1,401	1,793	2,259	2,756
Parts	835	971	1,121	1,171	1,415	1,817	2,340	2,995	3,774	4,604
Maintenance	33	54	79	80	101	130	167	214	269	328
Others	25	73	54	79	123	221	486	622	784	957
Rev YoY %	*52%*	*32%*	*45%*	*37%*	*37%*	*35%*	*29%*	*28%*	*26%*	*22%*
Gross margin	45.7%	45.8%	41.1%	39.2%	42.3%	43.8%	44.8%	44.9%	44.9%	44.9%
Gross profit	2,168	2,870	3,722	4,850	7,194	10,039	13,231	16,955	21,363	26,063
Opex	**1,265**	**1,664**	**2,409**	**3,520**	**3,702**	**3,805**	**4,266**	**5,348**	**6,548**	**8,247**
Opex ratio	27%	27%	27%	28%	22%	17%	14%	14%	14%	14%
OP income	**903**	**1,206**	**1,313**	**1,330**	**3,492**	**6,233**	**8,965**	**11,607**	**14,815**	**17,815**
OPM	*19%*	*19%*	*14%*	*11%*	*21%*	*27%*	*30%*	*31%*	*31%*	*31%*
Pre-tax profit	**1,259**	**2,010**	**1,709**	**2,190**	**4,481**	**6,899**	**9,663**	**12,306**	**15,514**	**18,514**
Net profit	**1,170**	**1,786**	**1,616**	**2,111**	**4,049**	**6,002**	**8,214**	**10,460**	**13,187**	**15,737**
YoY	16%	53%	-10%	31%	92%	48%	37%	27%	26%	19%
EPS	1.90	2.89	2.61	2.26	4.33	6.43	8.79	11.20	14.12	16.85
2030 Target P/E									56.0x	
12M target price (Rmb)						**573**				
TP implied P/E						**89**	**65**	**51**		

COE assumption	
Beta	1.20
Risk free	3.5%
Market risk premium	6.5%
COE	**11%**


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 8: AMEC P&L Summary

Rmb mn	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26E	3Q26E	4Q26E	2022	2023	2024	2025	2026E	2027E	2028E
Revenue	2,173	2,787	3,102	4,322	2,915	3,814	4,420	5,855	4,740	6,264	9,065	12,385	17,004	22,899	29,518
Gross profit	903	1,074	1,175	1,698	1,163	1,604	1,946	2,481	2,168	2,870	3,722	4,850	7,194	10,039	13,231
Operating expense	668	876	931	1,044	773	921	947	1,061	1,265	1,664	2,409	3,520	3,702	3,805	4,266
Operating income	235	198	244	654	390	684	999	1,420	903	1,206	1,313	1,330	3,492	6,233	8,965
Pre tax profit	294	423	509	963	977	813	1,133	1,559	1,259	2,010	1,709	2,190	4,481	6,899	9,663
Net income	313	393	505	900	930	723	1,008	1,387	1,170	1,786	1,616	2,111	4,049	6,002	8,214
EPS (Rmb)	0.34	0.42	0.54	0.96	1.00	0.77	1.08	1.49	1.90	2.89	2.61	2.26	4.33	6.43	8.79
Margins / ratio															
Gross margin	41.5%	38.5%	37.9%	39.3%	39.9%	42.1%	44.0%	42.4%	45.7%	45.8%	41.1%	39.2%	42.3%	43.8%	44.8%
Opex ratio	30.7%	31.4%	30.0%	24.2%	26.5%	24.1%	21.4%	18.1%	26.7%	26.6%	26.6%	28.4%	21.8%	16.6%	14.5%
Operating margin	10.8%	7.1%	7.9%	15.1%	13.4%	17.9%	22.6%	24.2%	19.0%	19.3%	14.5%	10.7%	20.5%	27.2%	30.4%
Net margin	14.4%	14.1%	16.3%	20.8%	31.9%	19.0%	22.8%	23.7%	24.7%	28.5%	17.8%	17.0%	23.8%	26.2%	27.8%
QoQ															
Revenue	-39%	28%	11%	39%	-33%	31%	16%	32%							
Gross profit	-35%	19%	9%	44%	-32%	38%	21%	28%							
Operating income	-57%	-15%	23%	168%	-40%	75%	46%	42%							
Pre tax profit	-61%	44%	20%	89%	1%	-17%	39%	38%							
Net income	-55%	25%	29%	78%	3%	-22%	39%	38%							
Revenue	35%	51%	51%	21%	34%	37%	42%	35%	52%	32%	45%	37%	37%	35%	29%
Gross profit	25%	53%	31%	22%	29%	49%	66%	46%	61%	32%	30%	30%	48%	40%	32%
Operating income	-20%	24%	-21%	19%	66%	245%	309%	117%	109%	34%	9%	1%	163%	78%	44%
Pre tax profit	15%	54%	23%	26%	232%	92%	122%	62%	11%	60%	-15%	28%	105%	54%	40%
Net income	26%	47%	28%	28%	197%	84%	100%	54%	16%	53%	-10%	31%	92%	48%	37%
EPS	26%	45%	26%	27%	193%	84%	99%	54%	8%	52%	-10%	-13%	92%	48%	37%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 9: AMEC 12M forward P/E



Source: Eikon Datastream

Exhibit 10: AMEC Balance sheet and Cash flow statement

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Balance sheet						
Cash & equivalent	7,090	7,762	7,951	8,333	8,430	10,975
Net receivables	1,213	1,445	2,047	2,748	3,710	4,614
Inventory	4,260	7,039	7,170	8,956	10,775	15,552
Other current asset	2,523	1,656	1,765	1,765	1,765	1,765
Total current assets	**15,087**	**17,901**	**18,934**	**21,801**	**24,680**	**32,906**
Net PP&E	1,988	2,716	2,829	2,953	3,015	3,261
Net intangibles	687	693	1,286	3,528	4,850	6,290
Total investments	1,020	870	1,445	1,445	1,445	1,445
Other long-term assets	2,744	4,038	5,352	5,352	5,352	5,352
Total assets	**21,526**	**26,218**	**29,846**	**35,079**	**39,342**	**49,254**
Account payables	1,305	1,680	1,856	3,519	2,471	5,115
Short-term debt	510	36	19	19	19	19
Total current liabilities	**3,624**	**5,634**	**6,202**	**7,865**	**6,816**	**9,461**
Long-term debt	-	721.80	730.40	730.40	730.40	730.40
Total liabilities	**3,624**	**5,634**	**6,202**	**7,865**	**6,816**	**9,461**
Total long-term liabilities						
Total common equity	**17,826**	**19,737**	**22,695**	**26,277**	**31,588**	**38,856**
Minority interest	(3.0)	(1.4)	34.2	22.2	22.2	22.2
Total Equity	**17,823**	**19,736**	**22,729**	**26,299**	**31,610**	**38,878**
BVPS	19.4	21.4	24.6	28.5	34.2	42.1

Cash conversion cycle						
Account receivable days	56	54	51	51	51	51
Inventory days	412	386	344	300	280	295
Account payable days	122	102	86	100	85	85
Cash conversion cycle	346	337	310	251	246	261
Ratios						
ROE (common)	10.7%	8.6%	10.0%	16.5%	20.7%	23.3%
ROA	8.6%	6.8%	7.5%	12.5%	16.1%	18.5%
Net cash per share (Rmb)	10.6	11.3	7.7	8.1	8.2	10.9
Net debt as % of total equity	-36.9%	-35.5%	-31.7%	-28.8%	-24.3%	-26.3%

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Cash flow statement						
Net income	1,786	1,616	2,111	4,049	6,002	8,214
D&A add-back	161	248	918	930	1,204	1,352
Minorities add-back	(2)	(1)	(47)	(12)	-	-
Net(inc)/dec working capital	(1,014)	(2,635)	(558)	(823)	(3,830)	(3,037)
Other operating cash flow	(1,908)	2,231	(129)	-	-	-
Cash flow from operations	**(977)**	**1,458**	**2,295**	**4,144**	**3,377**	**6,529**
Capital expenditures	(870)	(895)	(1,950)	(2,970)	(2,588)	(3,038)
Investments	3,062	2,382	575	-	-	-
Others	(364)	(841)	(730)	-	-	-
Cash flow from investments	**1,827**	**646**	**(2,105)**	**(2,970)**	**(2,588)**	**(3,038)**
Dividend paid (common & pref)	(138)	(200)	(243)	(466)	(691)	(946)
Inc/(dec) in debt	(3)	248	(8)	-	-	-
Change in common stock	673	788	944	-	-	-
Other financing cash flows	(311)	(837)	(511)	-	-	-
Cash flow from financing	**223**	**(2)**	**182**	**(466)**	**(691)**	**(946)**
Total cash flow	**1,073**	**2,103**	**372**	**708**	**98**	**2,545**
Free cash flow	**(1,847)**	**563**	**345**	**1,174**	**789**	**3,491**
Ratio						
Capex to revenue	13.9%	9.9%	15.7%	17.5%	11.3%	10.3%

Source: Company data, Goldman Sachs Global Investment Research

ACMR (ACMR.US, Buy)

Earnings revision: We raise earnings by 3%/ 7% in 2027-28E mainly on higher revenues and improving Opex ratio. We revise up the revenues of cleaning tools for advanced

nodes clients, and accelerated product expansion to innovative PECVD tools. We lower opex ratio in 2028E to reflect larger business scale and improving efficiency.

Exhibit 11: Earnings revision

	2026E			2027E			2028E		
(US$ mn)	New	Old	Diff	New	Old	Diff	New	Old	Diff
Revenue	1,238	1,238	0%	1,690	1,655	2%	2,022	1,986	2%
Gross profit	566	566	0%	775	759	2%	920	903	2%
Opering income	205	205	0%	301	292	3%	367	346	6%
Pre-tax profit	207	207	0%	312	304	3%	378	357	6%
Net income	138	138	0%	214	207	3%	260	243	7%
Margins									
Gross margin	45.7%	45.7%	0ppts	45.9%	45.8%	0ppts	45.5%	45.5%	0ppts
Operating margin	16.5%	16.5%	0ppts	17.8%	17.7%	0.1ppts	18.1%	17.4%	0.7ppts
Net margin	11.2%	11.2%	0ppts	12.6%	12.5%	0.1ppts	12.9%	12.2%	0.6ppts

Source: Company data, Goldman Sachs Global Investment Research

Valuation: We change the valuation methodology from near-term P/E to 2030E discounted P/E to capture the long-term growth opportunities. **Our 12-month target price is US$164 (vs. previously at US$109.4)**. Our target multiple is based the correlation between peers' P/E vs. the sum of forward year NI growth and OPM, which is 40x 2030E discounted P/E target multiple, based on company's NI YoY at 18% and OPM at 18% in 2031E. We apply the 40x target P/E and discount it back to 2027E with a COE of 11%. Maintain Buy.

Exhibit 12: ACMR discounted P/E

USD mn	2022	2023	2024	2025	2026E	2027E	2028E	2029E	2030E	2031E
Revenue	**4,740**	**558**	**782**	**901**	**1,238**	**1,690**	**2,022**	**2,426**	**2,790**	**3,180**
Rev YoY %	*52%*	*-88%*	*40%*	*15%*	*37%*	*37%*	*20%*	*20%*	*15%*	*14%*
Gross margin	45.7%	49.5%	50.1%	44.4%	45.7%	45.9%	45.5%	45.0%	44.0%	44.0%
Gross profit	2,168	276	392	400	566	775	920	1,092	1,227	1,399
Opex	**1,265**	**180**	**241**	**291**	**361**	**474**	**553**	**679**	**753**	**840**
Opex ratio	27%	32%	31%	32%	29%	28%	27%	28%	27%	26%
OP income	**903**	**96**	**151**	**109**	**205**	**301**	**367**	**412**	**474**	**560**
OPM	*19%*	*17%*	*19%*	*12%*	*17%*	*18%*	*18%*	*17%*	*17%*	*18%*
Pre-tax profit	**1,259**	**116**	**166**	**123**	**207**	**312**	**378**	**427**	**489**	**575**
Net profit	**1,170**	**77**	**104**	**82**	**138**	**214**	**260**	**321**	**383**	**451**
YoY	16%	-93%	34%	-21%	68%	55%	22%	23%	19%	18%
EPS	1.90	1.17	1.56	1.21	2.04	3.15	3.83	4.73	5.65	6.64
2030 Target P/E									40.0x	
12M target price (Rmb)						**164**				
TP implied P/E						**52**	**43**	**35**		

COE assumption	
Beta	1.20
Risk free	3.5%
Market risk premium	6.5%
COE	**11%**

The EPS data refers to diluted EPS


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 13: ACMR P&L Summary

US$ mn	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26E	3Q26E	4Q26E	2022	2023	2024	2025	2026E	2027E	2028E
Revenue	172	215	269	244	231	283	348	375	389	558	782	901	1,238	1,690	2,022
Gross profit	83	104	113	100	107	126	161	172	184	276	392	400	566	775	920
Operating expense	(57)	(73)	(84)	(77)	(71)	(90)	(104)	(96)	(125)	(180)	(241)	(291)	(361)	(474)	(553)
Operating income	26	32	29	23	36	36	57	76	59	96	151	109	205	301	367
Pre tax profit	27	38	49	21	30	39	60	79	67	116	166	123	207	312	378
Net income	20	30	36	8	17	26	41	54	39	77	104	82	138	214	260
EPS, diluted (US$)	0.30	0.44	0.52	0.12	0.25	0.38	0.59	0.78	0.60	1.17	1.56	1.21	2.04	3.15	3.83
Margins / ratio															
Gross margin	47.9%	48.5%	42.0%	40.9%	46.4%	44.4%	46.2%	45.8%	47.2%	49.5%	50.1%	44.4%	45.7%	45.9%	45.5%
Opex ratio	-32.9%	-33.8%	-31.3%	-31.4%	-30.7%	-31.8%	-29.9%	-25.5%	-32.0%	-32.3%	-30.8%	-32.2%	-29.2%	-28.1%	-27.4%
Operating margin	15.0%	14.7%	10.7%	9.4%	15.6%	12.6%	16.3%	20.3%	15.2%	17.2%	19.3%	12.1%	16.5%	17.8%	18.1%
Net margin	11.8%	13.8%	13.3%	3.3%	7.5%	9.3%	11.7%	14.4%	10.1%	13.9%	13.2%	9.1%	11.2%	12.6%	12.9%
QoQ															
Revenue	-23%	25%	25%	-9%	-5%	23%	23%	8%							
Gross profit	-26%	27%	8%	-12%	7%	17%	28%	7%							
Operating income	-41%	23%	-9%	-20%	57%	-1%	59%	34%							
Pre tax profit	-52%	40%	29%	-58%	44%	28%	55%	33%							
Net income	-34%	46%	21%	-78%	115%	52%	55%	33%							
YoY															
Revenue	13%	6%	32%	9%	34%	32%	29%	53%	50%	43%	40%	15%	37%	37%	20%
Gross profit	4%	8%	8%	-10%	30%	20%	42%	72%	60%	50%	42%	2%	41%	37%	19%
Operating income	2%	-16%	-35%	-48%	40%	13%	96%	230%	52%	62%	58%	-28%	87%	47%	22%
Pre tax profit	3%	-6%	15%	-63%	10%	1%	21%	280%	56%	73%	43%	-26%	68%	51%	21%
Net income	17%	23%	16%	-74%	-15%	-12%	13%	570%	4%	97%	34%	-21%	68%	55%	22%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 14: ACMR 12M foward P/E



Source: Eikon Datastream

Exhibit 15: ACMR Balance sheet and Cash flow statement

US$ mn	2023	2024	2025	2026E	2026E	2026E
Balance sheet						
Cash & equivalent	183	411	766	1,050	1,061	1,446
Net receivables	283	387	504	581	531	743
Inventory	545	598	703	586	918	651
Other current asset	164	87	464	453	453	453
Total current assets	**1,176**	**1,483**	**2,437**	**2,669**	**2,962**	**3,293**
Net PP&E	202	269	315	389	449	509
Net intangibles	10	17	21	17	17	17
Total investments	17	28	37	66	66	66
Other long-term assets	76	49	34	34	34	34
Total assets	**1,491**	**1,856**	**2,872**	**3,176**	**3,529**	**3,919**
Account payables	153	155	248	379	474	552
Short-term debt	38	77	109	109	109	109
Total current liabilities	501	641	746	877	972	1,050
Long-term debt	53.95	105.53	178.93	178.93	178.93	178.93
Total long-term liabilities	64	119	196	196	196	196
Total liabilities	**565**	**760**	**942**	**1,073**	**1,168**	**1,246**
Total common equity	**767**	**905**	**1,464**	**1,603**	**1,816**	**2,076**
Minority interest	159	191	466	501	545	597
Cash flow statement						
Net income	77	104	82	138	214	260
D&A add-back	-	-	-	-	-	-
Minorities add-back	20	28	28	35	44	52
Net(inc)/dec working capital	(215)	(154)	(130)	171	(186)	133
Other operating cash flow	38	178	-	-	-	-
Cash flow from operations	**(75)**	**152**	**(20)**	**344**	**71**	**445**
Capital expenditures	(62)	(82)	(60)	(60)	(60)	(60)
Investments	10	9	29	-	-	-
Others	45	61	-	-	-	-
Cash flow from investments	**(7)**	**(12)**	**(31)**	**(60)**	**(60)**	**(60)**
Dividend paid (common & pref)	-	-	-	-	-	-
Inc/(dec) in debt	15	91	105	-	-	-
Change in common stock	26	48	438	-	-	-
Other financing cash flows	(22)	(46)	-	-	-	-
Cash flow from financing	**19**	**92**	**543**	**-**	**-**	**-**
Total cash flow	**(65)**	**228**	**355**	**284**	**11**	**385**
Free cash flow	**(137)**	**70**	**(80)**	**284**	**11**	**385**

Source: Company data, Goldman Sachs Global Investment Research

Anji Micro (688019.SS, Buy)

Earnings revision: We raise earnings by 2%/ 4% in 2027-28E mainly on higher revenues. We revise up revenues of CMP Slurry and wet chemicals for advanced node clients, driven by rising capex spending of local clients, and rising adoption of Anji's solution.

Exhibit 16: Earnings revision

	2026E			2027E			2028E		
Rmb mn	New	Old	Diff(%)	New	Old	Diff(%)	New	Old	Diff(%)
Revenue	3,593	3,593	0%	4,752	4,687	1%	5,857	5,692	3%
Gross profit	2,077	2,077	0%	2,802	2,765	1%	3,451	3,348	3%
Op. income	1,297	1,297	0%	1,945	1,908	2%	2,510	2,407	4%
Net income	1,186	1,186	0%	1,790	1,756	2%	2,298	2,206	4%
Margins									
GM	57.8%	57.8%	0ppts	59.0%	59.0%	0ppts	58.9%	58.8%	0.1ppts
OPM	36.1%	36.1%	0ppts	40.9%	40.7%	0.2ppts	42.8%	42.3%	0.6ppts
NM	33.0%	33.0%	0ppts	37.7%	37.5%	0.2ppts	39.2%	38.8%	0.5ppts

Source: Company data, Goldman Sachs Global Investment Research

Valuation: We change the valuation methodology from near-term P/E to 2030E discounted P/E to capture the long-term growth opportunities. **Our 12-month target price is Rmb509 (vs. previously at Rmb293.08)**. Our target multiple is based on the correlation between peers' P/E vs. the sum of forward year NI growth and OPM, which is 46x 2030E discounted P/E target multiple, based on company's NI YoY at 18% and OPM at 18% in 2031E. We apply the 56x target P/E and discount it back to 2027E with a COE of 11%. Maintain Buy.

Exhibit 17: Anji Micro discounted P/E

Rmb mn	2022	2023	2024	2025	2026E	2027E	2028E	2029E	2030E	2031E
Revenue	**1,077**	**1,238**	**1,835**	**2,504**	**3,593**	**4,752**	**5,857**	**7,145**	**8,503**	**10,033**
Rev YoY %		*15%*	*48%*	*36%*	*43%*	*32%*	*23%*	*22%*	*19%*	*18%*
Gross margin	54.2%	55.8%	58.5%	56.7%	57.8%	59.0%	58.9%	59.0%	59.0%	59.0%
Gross profit	584	691	1,073	1,420	2,077	2,802	3,451	4,214	5,014	5,917
Opex	**265**	**368**	**515**	**621**	**780**	**857**	**941**	**1,127**	**1,324**	**1,555**
Opex ratio	25%	30%	28%	25%	22%	18%	16%	16%	16%	16%
OP income	**318**	**323**	**558**	**799**	**1,297**	**1,945**	**2,510**	**3,087**	**3,690**	**4,362**
OPM	*30%*	*26%*	*30%*	*32%*	*36%*	*41%*	*43%*	*43%*	*43%*	*43%*
Pre-tax profit	**339**	**440**	**568**	**849**	**1,318**	**1,989**	**2,553**	**3,167**	**3,770**	**4,442**
Net profit	**301**	**403**	**534**	**784**	**1,186**	**1,790**	**2,298**	**2,867**	**3,470**	**4,142**
YoY		34%	33%	47%	51%	51%	28%	25%	21%	19%
EPS	2.08	1.85	2.45	3.59	5.24	7.87	10.10	12.60	15.25	18.21
2030 Target P/E									46.0x	
12M target price (Rmb)						**509**				
TP implied P/E						**65**	**50**	**40**		

COE assumption	
Beta	1.20
Risk free	3.5%
Market risk premium	6.5%
COE	**11%**


Source: Company data, Goldman Sachs Global Investment Research

Exhibit 18: Anji Micro P&L Summary

(Rmb m)	1Q25	2Q25	3Q25	4Q25	1Q26	2Q26E	3Q26E	4Q26E	2022	2023	2024	2025	2026E	2027E	2028E
Revenue	545	596	671	692	724	876	992	1,001	1,077	1,238	1,835	2,504	3,593	4,752	5,857
Gross profit	304	340	382	395	402	510	587	578	584	691	1,073	1,420	2,077	2,802	3,451
Operating expense	129	134	176	182	167	167	220	226	265	368	515	621	780	857	941
Operating income	174	206	206	213	235	343	367	352	318	323	558	799	1,297	1,945	2,510
Pre tax profit	184	222	250	193	223	354	378	363	339	440	568	849	1,318	1,989	2,553
Net income	169	207	233	175	208	319	340	327	301	403	534	784	1,186	1,790	2,298
Margins / ratio															
Gross margin	55.7%	57.0%	57.0%	57.0%	55.5%	58.2%	59.2%	57.7%	54.2%	55.8%	58.5%	56.7%	57.8%	59.0%	58.9%
Opex ratio	23.7%	22.5%	26.3%	26.2%	23.1%	19.1%	22.2%	22.6%	24.7%	29.7%	28.1%	24.8%	21.7%	18.0%	16.1%
Operating margin	32.0%	34.5%	30.7%	30.8%	32.4%	39.2%	37.0%	35.2%	29.6%	26.1%	30.4%	31.9%	36.1%	40.9%	42.8%
Net margin	33.7%	37.2%	37.3%	27.9%	30.8%	40.4%	38.1%	36.2%	31.5%	35.6%	30.9%	33.9%	36.7%	41.9%	43.6%
QoQ															
Revenue	4%	9%	12%	3%	5%	21%	13%	1%							
Gross profit	0%	12%	12%	3%	2%	27%	15%	-2%							
Operating income	19%	18%	0%	4%	10%	46%	7%	-4%							
Pre tax profit	22%	21%	13%	-23%	15%	59%	7%	-4%							
Net income	20%	22%	13%	-25%	18%	53%	7%	-4%							
YoY															
Revenue	44%	42%	30%	32%	33%	47%	48%	45%	57%	15%	48%	36%	43%	32%	23%
Gross profit	37%	42%	24%	30%	32%	50%	54%	46%	66%	18%	55%	32%	46%	35%	23%
Operating income	50%	65%	21%	45%	35%	67%	78%	65%	197%	2%	72%	43%	62%	50%	29%
Pre tax profit	62%	62%	50%	29%	21%	60%	51%	88%	157%	30%	29%	50%	55%	51%	28%
Net income	61%	60%	47%	24%	23%	54%	46%	86%	141%	34%	33%	47%	51%	51%	28%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 19: Anji 12M forward P/E



Source: Eikon Datastream

Exhibit 20: Anji Micro Balance sheet and Cash flow statement

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Balance sheet						
Cash & equivalent	532	898	1,621	2,561	3,345	5,249
Net receivables	282	393	552	787	958	1,192
Inventory	427	618	1,050	944	1,567	1,531
Other current asset	101	118	103	96	96	96
Total current assets	1,342	2,026	3,326	4,388	5,966	8,069
Net PP&E	309	512	655	749	813	860
Net intangibles	80	79	74	66	60	55
Total investments	112	114	94	94	94	94
Other long-term assets	760	720	889	889	889	889
Total assets	**2,603**	**3,452**	**5,038**	**6,187**	**7,822**	**9,967**
Account payables	81	143	183	273	313	410
Short-term debt	42	198	194	194	194	194
Total current liabilities	193	467	488	579	619	716
Long-term debt	94.59	114.45	0.46	0.46	0.46	0.46
Total long-term liabilities	192	170	1,019	1,019	1,019	1,019
Total liabilities	**479**	**751**	**1,507**	**1,598**	**1,638**	**1,735**
Total common equity	**2,124**	**2,701**	**3,531**	**4,588**	**6,183**	**8,231**
Minority interest	-	1	1	1	1	1
Total Equity	**2,124**	**2,701**	**3,531**	**4,589**	**6,184**	**8,232**
BVPS	9.8	12.4	16.2	21.1	28.4	37.8
Cash conversion cycle						
Account receivable days	77	67	69	68	67	67
Inventory days	265	250	281	240	235	235
Account payable days	55	54	55	55	55	55
Cash conversion cycle	286	264	295	253	247	247
Ratios						
ROE	22.1%	22.1%	25.1%	29.2%	33.2%	31.9%
ROA	17.3%	17.6%	18.5%	21.1%	25.6%	25.8%
Net cash per share (Rmb)	1.8	2.7	6.5	10.5	13.8	22.2
Net debt as % of total equity	-18.6%	-21.7%	-40.4%	-51.6%	-51.0%	-61.4%

Rmb mn	2023	2024	2025	2026E	2027E	2028E
Cash flow statement						
Net income	403	534	784	1,186	1,790	2,298
D&A add-back	58	84	135	172	192	208
Minorities add-back	-	-	-	-	-	-
Net(inc)/dec working capital	(111)	(238)	(552)	(38)	(754)	(102)
Other operating cash flow	(13)	114	74	-	-	-
Cash flow from operations	**336**	**493**	**440**	**1,320**	**1,228**	**2,404**
Capital expenditures	(338)	(267)	(280)	(250)	(250)	(250)
Investments	38	2	(20)	-	-	-
Others	(16)	(86)	(431)	-	-	-
Cash flow from investments	**(316)**	**(352)**	**(731)**	**(250)**	**(250)**	**(250)**
Dividend paid (common & pref)	(35)	(39)	(85)	(129)	(195)	(250)
Inc/(dec) in debt	82	177	(118)	(0)	(0)	(0)
Change in common stock	251	80	73	-	-	-
Other financing cash flows	(124)	(95)	742	-	-	-
Cash flow from financing	**175**	**123**	**611**	**(129)**	**(195)**	**(250)**
Total cash flow	**203**	**366**	**723**	**940**	**783**	**1,904**
Free cash flow	**(2)**	**226**	**160**	**1,070**	**978**	**2,154**
Ratio						
Capex to revenue	27%	15%	11%	7%	5%	4%

Source: Company data, Goldman Sachs Global Investment Research

Price Target Risks and Methodology - NAURA

Valuation: We are Buy-rated on NAURA with a 12-month target price of Rmb1,200, which is based on 56x 2030E discounted P/E (discounted back to 2027E). Our target P/E

is derived from correlation between peers P/E to the sum of NI YoY and OPM.

Key downside risks: 1) Further US export restrictions on China semiconductor firms, which could delay their capacity expansion schedule and therefore reduce the demand for NAURA's equipment; 2) Slower-than-expected capacity expansion progress at NAURA's matured nodes customers, which could lead to slower revenue growth than we expect and therefore lower earnings vs. our current estimates.

Price Target Risks and Methodology - AMEC

Valuation: We are Buy-rated on AMEC with a 12-month target price of Rmb573, which is based on 56x 2030E discounted P/E (discounted back to 2027E). Our target P/E is derived from correlation between peers P/E to the sum of NI YoY and OPM.

Key downside risks: (1) Current trade restrictions do not specifically target matured node fabs, but if restrictions were to expand to matured nodes, it would further reduce demand for AMEC's products. (2) AMEC supplies etchers that can be used for 5nm production lines overseas (i.e., advanced nodes); if its ability to supply such products is hindered, it could lead to further downside risks. (3) Weaker-than-expected capex of major foundries in China.

Price Target Risks and Methodology - ACM Research

Valuation: We are Buy-rated on ACMR with a 12-month target price of US$164, which is based on 40x 2030E discounted P/E (discounted back to 2027E). Our target P/E is derived from correlation between peers P/E to the sum of NI YoY and OPM.

Key downside risks to our investment thesis: 1) stronger-than-expected competition in cleaning equipment; 2) a delay in R&D of new tools and technology, which could impact ACM Research's market share and revenue; 3) supply chain risk – some key components of ACM Research's products are from overseas suppliers, and logistics disruptions could impact its supply chain; 4) China-US trade tensions.

Price Target Risks and Methodology - Anji Micro

Valuation: We are Buy-rated on Anji Micro with a 12-month target price of Rmb509, which is based on 46x 2030E discounted P/E (discounted back to 2027E). Our target P/E is derived from correlation between peers P/E to the sum of NI YoY and OPM.

Key downside risks: 1) supply chain risks; 2) weaker semi client demand; and 3) weaker-than-expected product expansion.

Disclosure Appendix

Reg AC

We, Allen Chang, Verena Jeng and Ting Song, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Allen Chang Goldman Sachs (Asia) L.L.C., Verena Jeng Goldman Sachs (Asia) L.L.C., Ting Song Goldman Sachs (Asia) L.L.C..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

The rating(s) for ACM Research, AMEC, Anji Micro and NAURA is/are relative to the other companies in its/their coverage universe: AAC, ACM Research, AMEC, ASMPT, AVC, AccoTest, Anji Micro, Asus, Auras, BOE, BYDE, Biren, CR Micro, Cambricon, Chenbro, China Mobile (HK), China Telecom, China Tower Corp., China Unicom, Chinasoft Intl, Compal, Desay SV, E Ink, E-Town Semis, EHang, Empyrean, Eoptolink, Fositek, Foxconn Industrial Internet, Gigabyte, Gigadevice, Glodon Co., HTC Corp., Hikvision, Hon Hai, Horizon Robotics, Hua Hong, Huace Navigation, Huaqin Co.(A), Huaqin Co.(H), Hwatsing, Innolight, Inspur, Insta360, Inventec, JCET, Kematek, King Slide, Kingdee, Kingsoft Office, LandMark, Largan, Lenovo, Lingyi, Maxscend, Meitu, MetaX, Mitac, Montage (A), Montage (H), NAURA, NSIG, Nexchip, OmniVision, Pegatron, Pony AI Inc. (ADR), Pony AI Inc. (H), Quanta, RoboTechnik, Ruijie Networks, SG Micro, SICC, SMIC (A), SMIC (H), SZS, Sangfor, SenseTime, Shengyi Tech, Shennan Circuits, StarPower, Sunny Optical, TFC Optical, Thundersoft, Tongyu Communication, Transsion, UMT, UNIS, VPEC, Vanchip, VeriSilicon, Victory Giant, WNC, WUS, WeRide, Wistron, Wiwynn, YJ Semitech, YOFC, Yonyou, ZTE (A), ZTE (H), iFlytek

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the second most recent month end: AMEC (Rmb462.00) and NAURA (Rmb935.36)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: ACM Research ($126.89), AMEC (Rmb462.00) and Anji Micro (Rmb322.60)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: ACM Research ($126.89) and AMEC (Rmb462.00)

Goldman Sachs makes a market in the securities or derivatives thereof: ACM Research ($126.89)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe


	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	50%	34%	16%	65%	60%	45%

As of April 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,074 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.


Price target and rating history chart(s)




The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Target price history table(s)

NAURA (002371.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
22-May-26	818.00	669.00
12-May-26	719.00	581.45
30-Apr-26	638.00	536.99
21-Apr-26	600.00	450.36
01-Nov-25	572.00	407.05
24-Sep-25	561.00	460.68
29-Aug-25	492.00	372.50
28-Apr-25	597.00	336.61
14-Jan-25	540.00	289.89
14-Nov-24	576.00	332.82
14-Oct-24	503.00	273.34
09-Oct-24	502.00	300.00
11-Sep-24	438.00	222.56
11-Jul-24	432.00	232.05
29-Apr-24	428.00	239.26
25-Mar-24	379.00	234.67
15-Jan-24	334.00	171.84
07-Dec-23	315.00	160.39

AMEC (688012.SS)

Date of report	Target price (Rmb)	Closing price (Rmb)
20-May-26	614.00	329.08
15-May-26	538.00	290.54
28-Apr-26	471.00	243.13
04-Apr-26	462.00	196.98
06-Jan-26	459.00	221.26
22-Dec-25	424.00	183.03
30-Oct-25	423.00	201.37
26-Sep-25	386.00	194.63
23-Sep-25	340.00	187.92
29-Aug-25	299.00	143.74
18-Jul-25	266.00	122.32
11-Mar-25	275.00	137.38
15-Jan-25	214.70	125.09
13-Nov-24	200.70	162.75
14-Mar-24	177.00	101.67
27-Oct-23	176.00	111.11
14-Oct-23	165.00	109.28
24-Aug-23	158.00	89.80

NAURA (002371.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
31-Oct-23	294.00	189.63
13-Oct-23	310.00	184.22
29-Aug-23	307.00	193.64
16-Jul-23	344.00	221.41

AMEC (688012.SS)

Date of report	Target price (Rmb)	Closing price (Rmb)
17-Jul-23	167.00	93.83

Anji Micro (688019.SS)

Date of report	Target price (Rmb)	Closing price (Rmb)
28-Apr-26	381.00	198.38
11-Mar-26	380.00	189.05
19-Jan-26	377.00	223.35
09-Jan-26	331.00	206.54
06-Jan-26	290.00	180.17
07-Nov-25	220.00	152.57
25-Sep-25	194.00	167.95
31-Aug-25	170.00	135.08
01-Jun-25	194.00	100.85
03-Mar-25	176.00	95.27
08-Nov-24	160.00	96.24
01-Sep-24	140.00	66.60
11-Jul-24	144.00	66.73
29-Apr-24	183.00	74.44
01-Mar-24	182.00	69.59
31-Oct-23	188.00	88.29
14-Oct-23	179.00	83.71
31-Aug-23	170.00	71.12
25-Jul-23	189.00	68.80

ACM Research (ACMR)

Date of report	Target price ($)	Closing price ($)
29-May-26	109.40	86.56
26-May-26	95.50	86.46
07-May-26	83.80	59.20
01-Mar-26	82.00	55.68
14-Feb-26	95.20	64.84
22-Jan-26	62.70	51.67
18-Jan-26	55.40	53.62
05-Nov-25	48.50	31.14
01-Oct-25	52.30	43.78
21-Sep-25	45.80	35.89
24-Aug-25	40.10	30.53
10-Aug-25	35.30	23.94
10-May-25	35.70	22.19
27-Feb-25	35.30	26.10
15-Jan-25	31.00	17.89
07-Nov-24	36.00	20.60
07-Aug-24	35.00	17.59
09-May-24	39.00	25.29
29-Apr-24	38.00	26.73
29-Feb-24	39.00	30.92
10-Jan-24	22.10	21.15
16-Nov-23	19.50	17.93
08-Nov-23	17.30	17.69
30-Oct-23	17.00	12.81
11-Oct-23	18.20	20.07
31-Aug-23	16.20	17.56
04-Aug-23	14.20	12.54
20-Jul-23	12.80	12.87

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain

Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details, a copy of the annual compliance audit report and other relevant information and disclosures can be found at this link: https://www.goldmansachs.com/worldwide/india/research-analyst. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities

and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs.

This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.